3rd Quarter - Report

THE NICKLES GROUP, LLC for AMGEN

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 5376 (P.L. 117-169), the Inflation Reduction Act and issues regarding drug pricing. H.R. 3517 / S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021. Issues related to the Self-Administered Drug (SAD) List. Issues regarding ESRD payments.

LobbyistCovered position, as disclosed
BRETT BAKER —
GREG D'ANGELO —
MARY BETH SAVARY TAYLOR —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5376 (117th), S. 1943 (117th), H.R. 3517 (117th)

Health Issues HCR

S. 4348, FDASLA Act of 2022 and H.R. 7667, Food and Drug Amendments of 2022. Issues regarding timely access to medications.

LobbyistCovered position, as disclosed
BRETT BAKER —
GREG D'ANGELO —
MARY BETH SAVARY TAYLOR —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7667 (117th), S. 4348 (117th)

Copyright/Patent/Trademark CPT

S. 2774, Pride in Patent Ownership Act. S. 4430, Interagency Patent Coordination and Improvement Act of 2022.

LobbyistCovered position, as disclosed
JEFF CHOUDHRY New U.S. Rep. Trent Franks, Legislative Director; U.S. Rep. Trent Franks, Legislative Assistant / Staff Assistant; House Small Business Committee, Intern
GREG D'ANGELO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2774 (117th), S. 4430 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.